Compare RCI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCI | RPRX |
|---|---|---|
| Founded | 1960 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 16.2B |
| IPO Year | N/A | 2020 |
| Metric | RCI | RPRX |
|---|---|---|
| Price | $37.58 | $39.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $34.50 | ★ $46.00 |
| AVG Volume (30 Days) | 894.8K | ★ 4.3M |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.81% | 2.21% |
| EPS Growth | ★ 341.45 | N/A |
| EPS | ★ 8.96 | 1.75 |
| Revenue | ★ $15,091,643,989.00 | $2,349,844,000.00 |
| Revenue This Year | $7.45 | $37.13 |
| Revenue Next Year | $5.57 | $1.48 |
| P/E Ratio | ★ $4.18 | $22.68 |
| Revenue Growth | 2.75 | ★ 3.70 |
| 52 Week Low | $23.18 | $24.05 |
| 52 Week High | $40.26 | $41.24 |
| Indicator | RCI | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 57.50 |
| Support Level | $37.42 | $39.24 |
| Resistance Level | $39.25 | $40.50 |
| Average True Range (ATR) | 0.65 | 0.91 |
| MACD | -0.16 | -0.08 |
| Stochastic Oscillator | 8.47 | 76.02 |
Rogers Communications is the largest wireless service provider in Canada with more than 11 million subscribers, equating to one-third of the total Canadian market. Rogers' wireless business accounts for more than half of total revenue and has been growing at a higher rate than other segments. The cable segment, which provides about 38% of total revenue after acquiring Shaw, offers home internet, television, and landline phone service to consumers and businesses. Remaining sales come from Rogers' media unit, which owns and operates various television and radio stations and the Toronto Blue Jays. Rogers' significant exposure to sports also includes ownership stakes in the Maple Leafs, Raptors, Toronto FC, and Argonauts.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.